Decide at what price you'd be comfortable buying and we'll help you stay ready.
Heidelberg Pharma is a German biotechnology company focused on cancer drugs. It does not sell a consumer product; instead, it develops antibody-drug conjugates, or ADCs, that attach a toxic payload to an antibody so the medicine can target cancer cells more precisely. Its best-known work is based on its ATAC technology, which uses a toxin called amanitin.
The company makes money in two main ways: by advancing its own drug candidates and by working with pharmaceutical partners on research and licensing deals. Partners pay for access to its technology, and the company can also earn milestone payments and royalties if those drug programs succeed. In that model, Heidelberg Pharma acts as a technology owner and drug developer rather than a large-scale drug manufacturer.
For beginners, the key point is that Heidelberg Pharma sits in the early-to-mid stage of the cancer drug value chain. It sells scientific know-how, drug candidates, and platform access to other drug companies, while aiming to turn its own research into future medicines for patients with hard-to-treat cancers.
Alpha Spread
Preferences
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
New to Alpha Spread? Create free account
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more